Articles

Tucatinib added to trastuzumab and capecitabine resulted in a substantial and permanent improvement of progression-free survival and overall survival for all patients with HER2-positive metastatic breast cancer with brain metastases, as confirmed by results from the HER2CLIMB study. Read More ›

Tucatinib-containing therapy resulted in a tumor volume reduction of >80%. Tucatinib was found to be highly effective when combined with paclitaxel plus trastuzumab plus pertuzumab. Read More ›

Tyrosine kinase inhibitor (TKI) treatments show equal overall survival and progression-free survival (PFS) benefits in patients with HER2-positive breast cancer with and without brain metastases. Read More ›

The combination regimen of tucatinib, palbociclib, and letrozole in patients with hormone receptor–positive, HER2-positive breast cancer with brain metastases demonstrates an improved central nervous system progression-free survival in a small group of patients. Read More ›

Tucatinib-trastuzumab-capecitabine combination therapy has been shown to double the overall survival in patients with HER2-positive breast cancer with leptomeningeal metastases. Read More ›

Telehealth visits provide increased access to care for oncology patients across multiple demographics with reported high patient satisfaction with level of care. Read More ›

Improved understanding of potential risk factors associated with weight gain will allow identification of at-risk patients and intervention for improved outcomes. Read More ›

The VA CARES program provides coordinated cancer care for veterans prescribed oral antineoplastic therapies who may lack access to comprehensive medication management resources. Read More ›

Alpelisib plus fulvestrant combination therapy improves progression-free survival while maintaining effectiveness in patients with HR-positive/HER2-negative advanced breast cancer in a French early access study. Read More ›